|
MechanismCYP3A4 inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date07 Dec 2004 |
阿莫西林克拉维酸钾干混悬剂在健康受试者中随机、开放、两周期、双交叉的空腹/餐后状态下生物等效性试验
[Translation] Randomized, open-label, two-cycle, double-crossover bioequivalence study of amoxicillin-clavulanate potassium dry suspension in healthy subjects in the fasting/fed state
主要目的:
研究阿莫西林克拉维酸钾干混悬剂受试制剂和参比制剂在空腹/餐后状态下的药动学特征,通过预试验验证阿莫西林和克拉维酸钾在人体血浆中的分析方法、评估变异程度、优化采样时间,为正式试验提供参考依据;通过正式试验评价两制剂的生物等效性。
次要目的:
观察受试制剂和参比制剂在健康受试者中的安全性。
[Translation] main purpose:
To study the pharmacokinetic characteristics of the test preparation and reference preparation of amoxicillin-clavulanate potassium dry suspension in the fasting/postprandial state, and to verify the analysis of amoxicillin and clavulanate potassium in human plasma through pre-experiment Methods, evaluate the degree of variation, optimize the sampling time, and provide reference for the formal test; evaluate the bioequivalence of the two preparations through the formal test.
Secondary purpose:
The safety of the test preparation and the reference preparation in healthy subjects was observed.
100 Clinical Results associated with KBN-Zhejiang Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with KBN-Zhejiang Pharmaceutical Co., Ltd.
100 Deals associated with KBN-Zhejiang Pharmaceutical Co., Ltd.
100 Translational Medicine associated with KBN-Zhejiang Pharmaceutical Co., Ltd.